The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial

C. Marques Da Silva (SP, Brazil), D. Silva Queiroz (SP, Brazil), R. Athanazio (SP, Brazil), S. Dal Corso (SP, Brazil), S. Rached (SP, Brazil), A. Lunardi (SP, Brazil), R. Vitorasso (SP, Brazil), H. Moriya (SP, Brazil), A. Fonseca (SP, Brazil), C. Carvalho (SP , Brazil)

Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases
Session: Exercise tolerance and functional status across respiratory diseases
Session type: E-poster session
Number: 286
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Marques Da Silva (SP, Brazil), D. Silva Queiroz (SP, Brazil), R. Athanazio (SP, Brazil), S. Dal Corso (SP, Brazil), S. Rached (SP, Brazil), A. Lunardi (SP, Brazil), R. Vitorasso (SP, Brazil), H. Moriya (SP, Brazil), A. Fonseca (SP, Brazil), C. Carvalho (SP , Brazil). The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial. 286

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



Acute effects of nasal high-flow during exercise in COPD patients after an exacerbation : a randomized controlled cross-over trial
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019

Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017
Year: 2018



A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 502s
Year: 2006

Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 525s
Year: 2007

A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study
Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021
Year: 2021



Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results
Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation
Year: 2008


Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005